Comparative Pharmacology
Head-to-head clinical analysis: EMTRICITABINE versus EMZAHH.
Peer-Reviewed Evidence
Head-to-head clinical analysis: EMTRICITABINE versus EMZAHH.
EMTRICITABINE vs EMZAHH
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Nucleoside reverse transcriptase inhibitor; phosphorylated to emtricitabine triphosphate which competes with endogenous deoxycytidine triphosphate and incorporates into viral DNA causing chain termination.
EMZAHH is a monoclonal antibody that targets and binds to the human epidermal growth factor receptor 2 (HER2), inhibiting downstream signaling pathways involved in cell proliferation and survival.
200 mg orally once daily, typically in combination with other antiretroviral agents.
10 mg orally twice daily without regard to meals.
None Documented
None Documented
Terminal elimination half-life is approximately 10 hours (range 8–12 hours) in adults with normal renal function; prolonged to >20 hours in severe renal impairment (CrCl <30 mL/min).
Clinical Note
moderateEmtricitabine + Ribavirin
"Emtricitabine may increase the hepatotoxic activities of Ribavirin."
Clinical Note
moderateLamivudine + Emtricitabine
"The risk or severity of adverse effects can be increased when Lamivudine is combined with Emtricitabine."
Clinical Note
moderateGanciclovir + Emtricitabine
"The risk or severity of adverse effects can be increased when Ganciclovir is combined with Emtricitabine."
Clinical Note
moderateValganciclovir + Emtricitabine
Terminal elimination half-life 12 hours, requiring twice-daily dosing for steady state
Renal: approximately 86% of the dose is excreted unchanged in urine via glomerular filtration and active tubular secretion. Biliary/fecal: minimal (<14% as unchanged drug and metabolites in feces).
Renal 40% unchanged, fecal 50% as metabolites, biliary 10%
Category C
Category C
Antiretroviral, NRTI
Antiretroviral, Integrase Inhibitor + NRTIs
"The risk or severity of adverse effects can be increased when Valganciclovir is combined with Emtricitabine."